Provided by Tiger Fintech (Singapore) Pte. Ltd.

Edgewise Therapeutics, Inc.

16.40
+0.94006.08%
Post-market: 16.400.00000.00%19:52 EDT
Volume:1.22M
Turnover:19.79M
Market Cap:1.72B
PE:-11.33
High:16.54
Open:15.55
Low:14.91
Close:15.46
Loading ...

Guggenheim Starts Edgewise Therapeutics With Buy Rating, $41 Price Target

MT Newswires Live
·
Yesterday

Guggenheim starts Edgewise with Buy on ‘compelling entry point’

TIPRANKS
·
Yesterday

Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More

Zacks
·
10 Apr

Edgewise Therapeutics (EWTX): Among Unstoppable Stocks That Could Double Your Money

Insider Monkey
·
06 Apr

Major Stake Acquisitions Signal Confidence in Edgewise Therapeutics

TIPRANKS
·
05 Apr

Edgewise Therapeutics Downgraded Following Safety Issues in Heart Drug Trial

GuruFocus.com
·
04 Apr

Edgewise Therapeutics Says Believes Atrial Fibrillation Not Driven by EDG-7500 in Phase 2 Trial, RBC Says

MT Newswires Live
·
04 Apr

Edgewise Therapeutics Cut to Sector Perform From Sector Outperform by Scotiabank

Dow Jones
·
03 Apr

RBC Lowers Price Target on Edgewise Therapeutics to $52 From $56, Keeps Outperform, Speculative Risk

MT Newswires Live
·
03 Apr

U.S. RESEARCH ROUNDUP-Alphabet, Amazon, Meta

Reuters
·
03 Apr

Edgewise Therapeutics Is Maintained at Overweight by Piper Sandler

Dow Jones
·
03 Apr

BUZZ-U.S. STOCKS ON THE MOVE-M-tron, Rocket Companies, TKO Group

Reuters
·
03 Apr

BUZZ-Edgewise falls on safety, efficacy doubts for heart disease drug

Reuters
·
02 Apr

Edgewise Therapeutics Shares Down 32.9% After Mid-Stage Trial Data of Co's Heart Disease Drug

THOMSON REUTERS
·
02 Apr

Edgewise Therapeutics 9.935M share Spot Secondary priced at $20.13

TIPRANKS
·
02 Apr

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday Ahead of US Tariffs Announcement

MT Newswires Live
·
02 Apr

Morning Brew: Folksam Divests Tesla Amid Labor Concerns

GuruFocus
·
02 Apr

Edgewise Therapeutics Shares Tumble on Underwritten Public Offering Pricing

Dow Jones
·
02 Apr

Edgewise Therapeutics Reports New Results From Phase 2 Hypertrophic Cardiomyopathy Trial

MT Newswires Live
·
02 Apr

Edgewise Therapeutics Prices $200 Million Offering

MT Newswires Live
·
02 Apr